FDA Expands Access Program for Ischemic Heart Failure Treatment System

FDA sign

The U.S. FDA has approved BioVentrix’s application for an Expanded Access Program for the Revivent TC System to treat ischemic heart failure.

24x7 | Leading Resource for Healthcare Technology Management Professionals